Uniqure NV
QURE
View Detailed Chart
30.840USD
+4.690+17.93%
Close 11/11, 16:00（ET）Quotes delayed by 15 min
1.92BMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+17.93%
5 Days
+1.31%
1 Month
-49.90%
6 Months
+141.13%
Year to Date
+74.63%
1 Year
+302.61%
View Detailed Chart
TradingKey Stock Score of Uniqure NV
Currency: USD Updated: 2025-11-10Key Insights
The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a very weak market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Uniqure NV's Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
14
analysts
Buy
Current Rating
59.182
Target Price
+112.96%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Uniqure NV Highlights
StrengthsRisks
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
Growing
The company is in a growing phase, with the latest annual income totaling USD 27.12M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 27.12M.
Undervalued
The company’s latest PE is -6.70, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 55.15M shares, decreasing 11.98% quarter-over-quarter.
Held by Louis Moore Bacon
Star Investor Louis Moore Bacon holds 175.00K shares of this stock.
Uniqure NV News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Uniqure NV Info
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
Ticker SymbolQURE
CompanyUniqure NV
CEOMr. Matthew (Matt) Kapusta, CPA
Websitehttps://www.uniqure.com/
Related Instruments
+2.27%
+2.88%
+2.98%
+1.84%
+2.59%
+4.84%
+4.57%
+6.99%
+3.73%
+4.57%
+2.03%
+1.90%
-0.31%
+3.08%
+2.26%
+3.08%
0.00%
+3.03%
+2.32%
+2.28%Popular Symbols
